# A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

> **NCT05137847** · — · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 118 (actual)

## Conditions studied

- Lymphoma, T-cell, Peripheral
- Lymphoma, T-cell, Cutaneous

## Interventions

- **DRUG:** Remitoro

## Key facts

- **NCT ID:** NCT05137847
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-24
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05137847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05137847, "A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05137847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*